Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069782 | 1.00 | CDK1 (0.33) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL7069783 | 1.00 | CDK1 (0.33) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| Maleic Acid SCHEMBL648967 | 0.90 | HRH4 (0.41) | HRH4HRH3LMNAHTTNPSR1 | |
| Fumaric Acid SCHEMBL650644 | 0.90 | HRH4 (0.41) | HRH4HRH3LMNAHTTNPSR1 | |
| SCHEMBL8524329 | 0.84 | HRH4 (0.41) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL9850899 | 0.81 | HRH4 (0.40) | HRH4HRH3LMNATSHRHTT | |
| SCHEMBL7625072 | 0.79 | GPR84 (0.42) | HRH4HRH3 | |
| SCHEMBL7624480 | 0.79 | — | — | |
| SCHEMBL7069730 | 0.79 | — | — | |
| SCHEMBL7624474 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6166060-A | 1H-4(5)-substituted imidazole derivatives | GLIATECH, INC. (US) | 2000-12-26 | — | — | US | claimed |
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | GLIATECH, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6448282-B1 | H3 HISTAMINE RECEPTOR ANTAGONIST ACTIVITY; ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE, DEPRESSION, SCHIZOPHRENIA, NARCOLEPSY, SLEEP APNEA, INSOMNIA, EPILEPSY, HYPOTHALAMIC DYSFUNCTION | GLIATECH, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6166060-A | 1H-4(5)-substituted imidazole derivatives | GLIATECH, INC. (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | HRH3, HRH4, HRH2 | CDK1 4626/4885CDK2 4258/4885CCNB1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.